Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rClone30-interleukin-12-interleukin-2
- Development stage
- Preclinical
- Lead developer
- Measurable Advantage Biologics, Inc.
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
rClone30-interleukin-12-interleukin-2 is a genetically engineered oncolytic Newcastle disease virus (NDV) strain (Clone 30) designed to express the immunostimulatory cytokines interleukin-12 (IL-12) and interleukin-2 (IL-2). This therapeutic approach combines the direct oncolytic properties of the NDV with the localized production of cytokines to enhance the systemic antitumor immune response. IL-12 promotes Th1 differentiation and activates NK and T cells, while IL-2 supports T-cell proliferation and survival. Preclinical studies in murine hepatoma models demonstrated that the dual-expression vector significantly inhibits tumor growth, increases the secretion of interferon-gamma (IFN-γ) and IP-10, and improves survival rates compared to viruses expressing either cytokine alone.
- Other names
- recombinant Newcastle disease virus expressing IL-12 and IL-2rClone30-interleukin-12-interleukin-2rClone-30-interleukin-12-interleukin-2rClone 30-interleukin-12-interleukin-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on rClone30-interleukin-12-interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rClone30-interleukin-12-interleukin-2.